The question bank is the fastest way to start, but PMHNP Helper also includes board-review planning, student resources, and plain-English guidance for psychiatric nurse practitioner students who are still learning the exam landscape.
A 38-year-old male with attention-deficit/hyperactivity disorder, combined presentation, was started on mixed amphetamine salts extended-release 20 mg daily four weeks ago. He reports improved focus during work hours and better task completion. His Adult ADHD Self-Report Scale (ASRS) score has decreased from 42 to 28. However, he notes the medication seems to wear off by 3 PM, leading to a return of distractibility and difficulty completing evening responsibilities including helping his children with homework. He also reports mild appetite suppression during the day and occasional difficulty falling asleep if he takes the medication after 9 AM. His blood pressure is 132/84 mmHg (baseline 124/78 mmHg) and heart rate is 88 bpm (baseline 72 bpm). The PMHNP is evaluating the stimulant treatment response. Which evaluation is most comprehensive?
Explanation
Evaluating stimulant response in adult ADHD requires a comprehensive assessment of symptom improvement, duration of medication effect across functional domains, side effect burden, and cardiovascular safety parameters. Validated tools like the ASRS should be used systematically, and adjustments should be made based on the integrated evaluation of efficacy, tolerability, and safety.
Key Takeaway
Stimulant treatment evaluation in adult ADHD must comprehensively address efficacy (including duration of coverage), side effects, and cardiovascular parameters, with systematic follow-up using validated measures after any treatment adjustments.